EXEL  valuation analysis

Name: Exelixis, Inc
Description: Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 06, 2021
Market cap: $5.59B (667th)
Sales(TTM): $1.75B (798th)
Earnings(TTM): $36.49M (1004th)

FFER: 1.71*
Actual price: $17.41
* Earnings were reported Aug 04, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-07-15
Price & Estimates
Sales & Earnings history (TTM)
No notables found through heuristics.
Earnings / MarketCap
Exelixis, Inc
"Biotechnology" industry
Sales / MarketCap
Exelixis, Inc
"Biotechnology" industry
Book / MarketCap
Exelixis, Inc
"Biotechnology" industry
Equity / Assets
Exelixis, Inc
"Biotechnology" industry